Brief: Enanta Pharmaceuticals Presents Data For Its Covid-19 And Respiratory Syncytial Virus Programs

Enanta Pharmaceuticals

17/04/2023 12:14

April 17 (Reuters) - Enanta Pharmaceuticals Inc
 ENTA.O :
    * ENANTA PHARMACEUTICALS PRESENTS DATA FOR ITS COVID-19 AND
RESPIRATORY SYNCYTIAL VIRUS PROGRAMS AT THE 33RD EUROPEAN
CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
    * ENANTA PHARMACEUTICALS PRESENTS DATA FOR ITS COVID-19 AND
RESPIRATORY SYNCYTIAL VIRUS PROGRAMS AT THE 33RD EUROPEAN
CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
    * ENANTA PHARMACEUTICALS INC: PRECLINICAL DATA DEMONSTRATE
EDP-235'S SUPERIOR TARGET TISSUE DISTRIBUTION AND CELL
PENETRATION COMPARED TO OTHER PROTEASE INHIBITORS
    * ENANTA PHARMACEUTICALS INC: NEW PRECLINICAL
PHARMACOKINETIC DATA
HIGHLIGHT EDP-323'S STRONG BIOAVAILABILITY AND FAVORABLE TISSUE
TARGETING

Source text for Eikon:  ID:nBw40qr6ta 
Further company coverage:  ENTA.O 

 ((Reuters.Briefs@thomsonreuters.com;))